Zydus Gains NMPA Approval for Venlafaxine Capsules in China
Filing Summary
Zydus Lifesciences Ltd has received approval from China’s National Medical Products Administration (NMPA) for its Venlafaxine Extended-Release Capsules in 75 mg and 150 mg dosages. This marks the company’s first approval from the NMPA. The capsules are indicated for treating Major Depressive Disorder, Generalised Anxiety Disorder, Social Anxiety Disorder, and Panic Disorder. Production will occur at Zydus’ facility in Moraiya, Ahmedabad. The approval represents a significant regulatory milestone for Zydus in the Chinese market.
Zydus Lifesciences Ltd has obtained approval from the National Medical Products Administration (NMPA) in China for its Venlafaxine Extended-Release Capsules, available in 75 mg and 150 mg dosages. The approval was announced on November 11, 2025.
The capsules are indicated for the treatment of Major Depressive Disorder, Generalised Anxiety Disorder, Social Anxiety Disorder, and Panic Disorder. They function by restoring the balance of serotonin and norepinephrine in the brain. The production of these capsules will take place at Zydus’ manufacturing facility located in Moraiya, Ahmedabad.
This approval is the first that Zydus has received from the NMPA in China, marking a significant regulatory achievement for the company in expanding its pharmaceutical offerings in the Chinese market.
Zydus Lifesciences Ltd is focused on the development and manufacturing of a wide range of pharmaceutical products. The company prioritizes expanding its global footprint through strategic regulatory approvals and enhancing its product portfolio to meet diverse healthcare needs.